AI Ovarian Cancer Detection DNA Methylation
Ovarian Cancer Early Detection via DNA Methylation: Key Facts
What: Researchers are investigating DNA methylation patterns in cell-free DNA (cfDNA) from blood samples as a potential biomarker for early detection of high-grade serous ovarian cancer (HGSC). Current detection methods (imaging, CA125) are often ineffective in early stages.
Where: University of Iowa, utilizing samples from their Gynecologic Oncology Bank. Analysis performed using Illumina Infinium MethylationEPIC BeadChip Array.
When: Research is ongoing, with a recent pilot case-control study completed. Initial findings reported in 2024 (date not explicitly stated in text).
Why it Matters:
Early diagnosis dramatically improves survival rates: Stage I diagnosis has 80-90% survival vs. 40-50% at Stage III/IV.
Current methods lack sensitivity/specificity: Leading to late-stage diagnoses in ~75% of cases.
Liquid biopsy potential: A blood test is less invasive than current diagnostic procedures.
High Accuracy: Initial models achieved 100% Area Under the Curve (AUC) in predicting HGSC.
What’s Next:
validation in larger,autonomous cohorts: The pilot study involved a relatively small sample size (99 HGSC samples,12 controls).
Clinical test progress: Refining the 9-probe model for practical implementation as a diagnostic test.
* Further research: Exploring the potential of this method for other subtypes of ovarian cancer and for monitoring treatment response.
study Data Summary:
| study Type | Sample Size (HGSC) | Sample Size (Control) | Methylation Analysis Platform | Probes Evaluated Initially | Probes in Final Predictive Model | AUC (Area Under the Curve) – Final Model |
|---|---|---|---|---|---|---|
| Pilot Case-Control | 99 | 12 | Illumina infinium MethylationEPIC BeadChip Array | 850,000+ | 9 | 100% |